Per Stirling Capital Management’s AbbVie ABBV Stock Holding History

Per Stirling Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.18M	Buy	10,045 +175	+2%	+$38.8K	0.24%	80
2025 Q4	$2.26M	Buy	9,870 +130	+1%	+$29.6K	0.25%	74
2025 Q3	$2.26M	Buy	9,740 +58	+0.6%	+$11.8K	0.27%	70
2025 Q2	$1.8M	Buy	9,682 +60	+0.6%	+$11.2K	0.23%	77
2025 Q1	$2.02M	Buy	9,622 +56	+0.6%	+$10.9K	0.29%	75
2024 Q4	$1.7M	Sell	9,566 -340	-3%	-$62.5K	0.24%	77
2024 Q3	$1.96M	Buy	9,906 +3	+0%	+$560	0.27%	69
2024 Q2	$1.7M	Buy	9,903 +5,534	+127%	+$917K	0.27%	68
2024 Q1	$796K	Buy	4,369 +245	+6%	+$42.2K	0.13%	104
2023 Q4	$639K	Buy	4,124 +7	+0.2%	+$1.02K	0.12%	108
2023 Q3	$614K	Buy	4,117 +100	+2%	+$14.7K	0.13%	102
2023 Q2	$541K	Sell	4,017 -447	-10%	-$65.5K	0.11%	114
2023 Q1	$711K	Sell	4,464 -470	-10%	-$71.9K	0.15%	85
2022 Q4	$797K	Buy	+4,934	New	+$757K	0.15%	91

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Per Stirling Capital Management's ABBV Position: Q1 2026 in Review

Per Stirling Capital Management increased its AbbVie (ABBV) stake by 1.8% in Q1 2026, buying an estimated $38.8K and bringing the position to 10,045 shares worth $2.18M. The position accounts for 0.24% of the portfolio, ranked #80.

Per Stirling Capital Management first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.26M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Per Stirling Capital Management held 10,045 shares of AbbVie worth $2.18M as of Q1 2026.
Per Stirling Capital Management bought 175 AbbVie shares in Q1 2026, an estimated $38.8K.
AbbVie made up 0.24% of Per Stirling Capital Management's portfolio in Q1 2026, its #80 holding.
Per Stirling Capital Management first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Per Stirling Capital Management's AbbVie position peaked at $2.26M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Per Stirling Capital Management's 13F filing for Q1 2026, filed 12 May 2026.